Binding of ligand-responsive EGFR mutants to chaperoning proteins HSP90 and CDC37
Binding of EGF to ligand-responsive EGFR mutants
EGF-induced dimerization of ligand-responsive EGFR mutants
Spontaneous dimerization of ligand-responsive EGFR mutants
Trans-autophosphorylation of activated ligand-responsive EGFR mutant dimers
EGFRvIII mutant binds chaperone proteins HSP90 and CDC37.
Ligand-independent dimerization of EGFRvIII mutant
Trans-autophosphorylation of EGFRvIII mutant dimers
Binding of GRB2:SOS1 complex to phosphorylated EGFR mutants
Binding of GRB2:SOS1 to p-EGFR mutants
SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with p-EGFR mutants)
Binding of SHC1 to p-EGFR mutants
Phosphorylation of SHC1 by p-EGFR mutants
Phosphorylated SHC1 in complex with p-EGFR mutants recruits GRB2:SOS1 complex
SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and p-EGFR mutants)
Binding of GRB2:GAB1:PIK3R1 complex to p-EGFR mutants
Binding of PI3K p110 subunit alpha (PIK3CA) to complex of GRB2:GAB1:PIK3R1 and p-EGFR mutants
Conversion of PIP2 to PIP3 by PI3K bound to phosphorylated EGFR mutants
PLC-gamma 1 binds to p-EGFR mutants
Phosphorylation of PLC-gamma 1 by p-EGFR mutants
Dissociation of phosphorylated PLC-gamma 1 from p-EGFR mutants
Binding of CBL to phosphorylated ligand-responsive EGFR mutants
Phosphorylation of CBL by ligand-responsive p-6Y-EGFR mutants
Inefficient ubiquitination of ligand-responsive EGFR mutants by phosphorylated CBL
HSP90 is inactivated by binding to benzaquinoid ansamycins
Non-covalent tyrosine kinase inhibitors bind and inactivate sensitive ligand-responsive EGFR cancer mutants
Covalent tyrosine kinase inhibitors bind and inactivate EGFR kinase domain mutant dimers resistant to non-covalent tyrosine kinase inhibitors
Covalent tyrosine kinase inhibitors bind and inhibit wild-type EGF:EGFR dimers
Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody
Signaling by constitutively active EGFR